FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285401211> ?p ?o ?g. }

• W4285401211 endingPage "1518" @default.
• W4285401211 startingPage "1509" @default.
• W4285401211 abstract "Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure. Given the expansion of noninvasive diagnosis with 99mTc-pyrophosphate (99mTc-PYP) scanning, and clinical use of the transthyretin stabilizer, tafamidis, we sought to examine the interplay of planar imaging heart-to-contralateral lung (H/CL) ratio, cardiac biomarkers, and survival probability in a contemporary cohort of patients referred for noninvasive evaluation of ATTR-CM.This single-center retrospective cohort study included 351 consecutive patients who underwent a standardized imaging protocol with 99mTc-PYP scanning for the evaluation of ATTR-CM from January 1, 2018, to January 1, 2020. After the exclusion of light chain amyloidosis, patients were characterized as scan consistent with ATTR (+ATTR-CM) or scan not consistent with ATTR (-ATTR-CM) using current guidelines. Linear regression was used to examine the relationship between biomarkers and H/CL and univariate Cox proportional hazards models were used to assess the probability of transplant-free survival.We included 318 patients in the analysis (n = 86 patients +ATTR-CM; n = 232 patients -ATTR-CM). The median follow-up time was 20.1 months. During the study period, 67% of +ATTR-CM patients received tafamidis (median treatment duration, 17 months). The median H/CL ratio was 1.58 (interquartile range, 1.40-1.75). An H/CL ratio of more than 1.6 or less than 1.6 did not seem to have an impact on survival probability in +ATTR-CM patients (P = .30; hazard ratio, 0.65; 95% confidence interval, 0.31-1.41). Cardiac biomarkers were poorly correlated with H/CL (troponin T, R2 = 0.024; N-terminal pro-B-type natriuretic peptide, R2 =0.023). The Gillmore staging system predicted survival probability in +ATTR-CM as well as in the entire cohort referred for scanning. There was a trend toward longer survival among those who were -ATTR-CM compared with +ATTR-CM (P = .051; hazard ratio, 0.64; 95% confidence interval, 0.40-1.00).At a large referral center, the intensity of 99mTc-PYP uptake (H/CL ratio) has neither correlation with cardiac biomarker concentrations nor prognostic usefulness in an analysis of intermediate term outcomes in the early therapeutics era. The H/CL ratio has diagnostic value, but offers little prognostic value in patients with ATTR-CM. Established staging schema were predictive of survival in this contemporary cohort, re-emphasizing the importance of cardiac biomarkers and renal function in assessing disease severity and prognosis." @default.
• W4285401211 created "2022-07-14" @default.
• W4285401211 creator A5015350489 @default.
• W4285401211 creator A5016319177 @default.
• W4285401211 creator A5026915222 @default.
• W4285401211 creator A5027454940 @default.
• W4285401211 creator A5039589228 @default.
• W4285401211 creator A5040169291 @default.
• W4285401211 creator A5040652950 @default.
• W4285401211 creator A5053472875 @default.
• W4285401211 creator A5071704226 @default.
• W4285401211 creator A5075687476 @default.
• W4285401211 creator A5081734725 @default.
• W4285401211 creator A5085780933 @default.
• W4285401211 date "2022-10-01" @default.
• W4285401211 modified "2023-09-24" @default.
• W4285401211 title "The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era." @default.
• W4285401211 cites W1843945506 @default.
• W4285401211 cites W2088038696 @default.
• W4285401211 cites W2163584170 @default.
• W4285401211 cites W2337532627 @default.
• W4285401211 cites W2507912906 @default.
• W4285401211 cites W2509971241 @default.
• W4285401211 cites W2513537837 @default.
• W4285401211 cites W2590841112 @default.
• W4285401211 cites W2735511149 @default.
• W4285401211 cites W2809989268 @default.
• W4285401211 cites W2810909862 @default.
• W4285401211 cites W2885222854 @default.
• W4285401211 cites W2888036721 @default.
• W4285401211 cites W2903969599 @default.
• W4285401211 cites W2948364217 @default.
• W4285401211 cites W2970218258 @default.
• W4285401211 cites W2971824914 @default.
• W4285401211 cites W3008860289 @default.
• W4285401211 cites W3028686367 @default.
• W4285401211 cites W3041983337 @default.
• W4285401211 cites W3093761233 @default.
• W4285401211 cites W3109552429 @default.
• W4285401211 doi "https://doi.org/10.1016/j.cardfail.2022.06.005" @default.
• W4285401211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35843490" @default.
• W4285401211 hasPublicationYear "2022" @default.
• W4285401211 type Work @default.
• W4285401211 citedByCount "2" @default.
• W4285401211 countsByYear W42854012112022 @default.
• W4285401211 countsByYear W42854012112023 @default.
• W4285401211 crossrefType "journal-article" @default.
• W4285401211 hasAuthorship W4285401211A5015350489 @default.
• W4285401211 hasAuthorship W4285401211A5016319177 @default.
• W4285401211 hasAuthorship W4285401211A5026915222 @default.
• W4285401211 hasAuthorship W4285401211A5027454940 @default.
• W4285401211 hasAuthorship W4285401211A5039589228 @default.
• W4285401211 hasAuthorship W4285401211A5040169291 @default.
• W4285401211 hasAuthorship W4285401211A5040652950 @default.
• W4285401211 hasAuthorship W4285401211A5053472875 @default.
• W4285401211 hasAuthorship W4285401211A5071704226 @default.
• W4285401211 hasAuthorship W4285401211A5075687476 @default.
• W4285401211 hasAuthorship W4285401211A5081734725 @default.
• W4285401211 hasAuthorship W4285401211A5085780933 @default.
• W4285401211 hasConcept C119060515 @default.
• W4285401211 hasConcept C121157162 @default.
• W4285401211 hasConcept C126322002 @default.
• W4285401211 hasConcept C164705383 @default.
• W4285401211 hasConcept C207103383 @default.
• W4285401211 hasConcept C2777607188 @default.
• W4285401211 hasConcept C2989005 @default.
• W4285401211 hasConcept C44249647 @default.
• W4285401211 hasConcept C50382708 @default.
• W4285401211 hasConcept C71924100 @default.
• W4285401211 hasConcept C72563966 @default.
• W4285401211 hasConceptScore W4285401211C119060515 @default.
• W4285401211 hasConceptScore W4285401211C121157162 @default.
• W4285401211 hasConceptScore W4285401211C126322002 @default.
• W4285401211 hasConceptScore W4285401211C164705383 @default.
• W4285401211 hasConceptScore W4285401211C207103383 @default.
• W4285401211 hasConceptScore W4285401211C2777607188 @default.
• W4285401211 hasConceptScore W4285401211C2989005 @default.
• W4285401211 hasConceptScore W4285401211C44249647 @default.
• W4285401211 hasConceptScore W4285401211C50382708 @default.
• W4285401211 hasConceptScore W4285401211C71924100 @default.
• W4285401211 hasConceptScore W4285401211C72563966 @default.
• W4285401211 hasIssue "10" @default.
• W4285401211 hasLocation W42854012111 @default.
• W4285401211 hasLocation W42854012112 @default.
• W4285401211 hasOpenAccess W4285401211 @default.
• W4285401211 hasPrimaryLocation W42854012111 @default.
• W4285401211 hasRelatedWork W2005101102 @default.
• W4285401211 hasRelatedWork W2023194007 @default.
• W4285401211 hasRelatedWork W2133235702 @default.
• W4285401211 hasRelatedWork W2895452769 @default.
• W4285401211 hasRelatedWork W2947523721 @default.
• W4285401211 hasRelatedWork W2999082981 @default.
• W4285401211 hasRelatedWork W3037194828 @default.
• W4285401211 hasRelatedWork W3192736130 @default.
• W4285401211 hasRelatedWork W3206037955 @default.
• W4285401211 hasRelatedWork W4229012974 @default.
• W4285401211 hasVolume "28" @default.
• W4285401211 isParatext "false" @default.

• next